StockNews.AI
RPRX
StockNews.AI
222 days

Royalty Pharma Announces Dividend Increase

1. Royalty Pharma announces a 5% dividend increase to $0.22 per share. 2. Payment scheduled for March 10, 2025, benefiting shareholders recorded by February 21, 2025. 3. Royalty Pharma's portfolio includes royalties from 35 leading therapies. 4. Company supports biopharmaceutical innovation through financing and royalty acquisitions. 5. The dividend announcement signals financial stability and potential for stock appreciation.

Dividend Change
+12.56%Current Return
VS
-1.53%S&P 500
$26.201/09 04:22 PM EDTEvent Start
$29.4901/10 10:28 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The dividend increase positively indicates financial health, similar to positive market reactions from past dividend hikes.

How important is it?

Dividend increases are crucial for income-oriented investors, likely attracting new interest in RPRX.

Why Short Term?

Investors may react quickly to the dividend announcement, impacting stock prices shortly.

Related Companies

VRTXGSKRHHBYJNJPFE
January 09, 2025 16:15 ET  | Source: Royalty Pharma plc NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@royaltypharma.com

Related News